Search results for " Drug Discovery"

showing 10 items of 54 documents

Reaction between Indazole and Pd-Bound Isocyanides-A Theoretical Mechanistic Study

2018

The mechanism of the addition of indazole (Ind)&mdash

Models Molecular3003Activation of small moleculesIndazolesisocyanideIsocyanidePharmaceutical ScienceDFT calculationProtonation010402 general chemistryDFT calculationsactivation of small molecule01 natural sciencesMedicinal chemistryArticleAnalytical Chemistrylcsh:QD241-441chemistry.chemical_compoundDeprotonationNucleophilelcsh:Organic chemistryTheoreticalModelsDrug DiscoveryNitrilesPhysical and Theoretical ChemistryMechanical PhenomenaIndazoleNucleophilic additionCyanidesMolecular Structure010405 organic chemistrynitrileDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryRegioselectivityMolecularIsocyanidesModels TheoreticalTautomer0104 chemical sciencesnucleophilic additionchemistryChemistry (miscellaneous)Settore CHIM/03 - Chimica Generale E InorganicaMolecular Medicinereaction mechanismActivation of small molecules; DFT calculations; Isocyanides; Nitriles; Nucleophilic addition; Reaction mechanism; Cyanides; Indazoles; Models Molecular; Molecular Structure; Palladium; Mechanical Phenomena; Models Theoretical; Analytical Chemistry; Chemistry (miscellaneous); Molecular Medicine; 3003; Drug Discovery3003 Pharmaceutical Science; Physical and Theoretical Chemistry; Organic ChemistryPalladium
researchProduct

Conformational response to ligand binding in phosphomannomutase2: insights into inborn glycosylation disorder.

2014

Background: Mutations in phosphomannomutase2 cause glycosylation disorder, a disease without a cure that will largely benefit from accurate ligand-bound models. Results: We obtained two models of phospomannomutase2 bound to glucose 1,6-bisphosphate and validated them with limited proteolysis. Conclusion: Ligand binding induces a large conformational transition in PMM2. Significance: We produce and validate closed-form models of PMM2 that represent a starting point for rational drug discovery.

Models MolecularPELEGlycosylationProtein Conformation1Molecular Sequence DataGlucose-6-PhosphateGlycosylation Inhibitor6-bisphosphate; PELE; computer modeling; drug discovery; glycosylation; glycosylation inhibitor; ligand-binding protein; phosphomannomutaseLigandsDrug DiscoveryAnimalsHumansAmino Acid Sequence16-BisphosphateProtein UnfoldingTemperatureLigand-binding Proteinphosphomannomutase 2 and mass spectrometryPhosphotransferases (Phosphomutases)PhosphomannomutaseMutationProteolysisMetabolism Inborn ErrorsMolecular BiophysicsPeptide HydrolasesProtein BindingComputer ModelingThe Journal of biological chemistry
researchProduct

Development and optimisation of computational tools for drug discovery

The aim of my PhD project was the development, optimisation, and implementation of new in silico virtual screening protocols. Specifically, this thesis manuscript is divided into three main parts, presenting some of the papers published during my doctoral work. The first one, here named CHEMOMETRIC PROTOCOLS IN DRUG DISCOVERY, is about the optimisation and application of an in house developed chemometric protocol. This part has been entirely developed at the University of Palermo - STEBICEF Department - under the guide of my supervisors. During the development of this part I have personally worked on the tuning and optimisation of the algorithm and on the docking campaigns to obtain molecul…

Molecular Modeling Computational aided drug discoverySettore CHIM/08 - Chimica Farmaceutica
researchProduct

Monoclonal antibodies in gastrointestinal cancers

2013

Introduction: Among gastrointestinal cancers, colorectal and gastric neoplasms are the most frequent. The development of new targeted drugs improved the efficacy of systemic therapy in advanced stages of those malignancies. Areas covered: This review highlights the main biological processes implicated in gastrointestinal cancer development and progression, such as angiogenesis and epidermal growth factor receptor (EGFR) signaling pathway. On these bases, anti-EGFR and anti-vascular endothelial growth factor (VEGF) monoclonal antibodies in colorectal and gastric cancer are discussed. Data about further monoclonal antibodies in development are also reported. Expert opinion: The use of monoclo…

OncologyVascular Endothelial Growth Factor AColorectal cancerAngiogenesisSettore MED/06 - Oncologia MedicaClinical BiochemistryPredictive Value of TestAntineoplastic AgentVascular Endothelial Growth Factor A; Animals; Antineoplastic Agents; Receptor Epidermal Growth Factor; Humans; Molecular Targeted Therapy; Predictive Value of Tests; Patient Selection; Antibodies Monoclonal; Genetic Testing; Individualized Medicine; Gastrointestinal Neoplasms; Tumor Markers Biological; Signal TransductionGastricDrug DiscoveryMonoclonalEpidermal growth factor receptorMolecular Targeted TherapyPrecision MedicineTumor MarkersColorectalCancerGastrointestinal NeoplasmsbiologyAntibody; Cancer; Colorectal; Gastric; Monoclonal; Animals; Antibodies Monoclonal; Antineoplastic Agents; Gastrointestinal Neoplasms; Genetic Testing; Humans; Individualized Medicine; Molecular Targeted Therapy; Patient Selection; Predictive Value of Tests; Receptor Epidermal Growth Factor; Signal Transduction; Tumor Markers Biological; Vascular Endothelial Growth Factor A; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical ScienceAntibodies MonoclonalIndividualized MedicineErbB ReceptorsTumor Markers BiologicalGastrointestinal NeoplasmMonoclonalGastric NeoplasmHumanReceptorSignal Transductionmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsMonoclonal antibodyAntibodiesPredictive Value of TestsInternal medicinemedicineBiomarkers TumorAnimalsHumansGastrointestinal cancerGenetic TestingAntibodyPharmacologyEpidermal Growth Factorbusiness.industryAnimalDrug Discovery3003 Pharmaceutical SciencePatient SelectionCancermedicine.diseaseBiologicalbiology.proteinReceptor Epidermal Growth Factorbusiness
researchProduct

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)

2009

Background and aim: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients' outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. Materials and Methods: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. Results: Positive hENT1 staining patients were…

Oncologymedicine.medical_specialtyPathologyCancer ResearchAntimetabolites Antineoplasticmedicine.medical_treatmentEquilibrative nucleoside transporter 1DeoxycytidineEquilibrative Nucleoside Transporter 1Statistical significanceInternal medicineDrug DiscoveryMedicineHumansHENT1PharmacologyChemotherapyUnivariate analysisPredictive markerBiliary tract cancer; Gemcitabine; HENT1; Predictive factor; Drug Discovery3003 Pharmaceutical Science; Pharmacology; Cancer Researchbiologybusiness.industryDrug Discovery3003 Pharmaceutical ScienceCancermedicine.diseaseImmunohistochemistryGemcitabineGemcitabineBiliary Tract NeoplasmsOncologybiology.proteinImmunohistochemistryBiliary tract cancerbusinessPredictive factormedicine.drug
researchProduct

Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls?

2015

Introduction: The discovery of molecular biomarkers and the advent of targeted therapies have led to a radical change in the treatment of several tumors, including NSCLC. In the last few years, the number of molecular biomarkers has rapidly increased, and a growing interest has been recently focused on their potential prognostic and predictive value in clinical settings. Areas covered: This review describes all the molecular biomarkers with prognostic and predictive value in NSCLC, including both clinically approved biomarkers, and emerging biomarkers under investigation in clinical trials. Liquid biopsy and applications of circulating biomarkers are also described. Expert opinion: The onco…

Oncologymedicine.medical_specialtyPathologyLung NeoplasmsOncogene Proteins Fusionmedicine.medical_treatmentClinical BiochemistryNSCLCprognostic biomarkersTargeted therapytissue biopsypredictive biomarkersInternal medicineCarcinoma Non-Small-Cell LungProto-Oncogene ProteinsDrug DiscoveryBiomarkers TumorMedicineHumansBiomarker discoveryLiquid biopsypredictive biomarkerprognostic biomarkerProtein Kinase InhibitorsPredictive biomarkerPharmacologyliquid biopsybusiness.industryDrug Discovery3003 Pharmaceutical Scienceliquid biopsy; NSCLC; predictive biomarkers; prognostic biomarkers; targeted therapy; tissue biopsy; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical ScienceProtein-Tyrosine KinasesPrognosistargeted therapyMolecular biomarkersPredictive valueClinical trialErbB ReceptorsCirculating biomarkersras Proteinsbusiness
researchProduct

Synthesis and photocytotoxic activity of [1,2,3]triazolo[4,5-h][1,6]naphthyridines and [1,3]oxazolo[5,4-h][1,6]naphthyridines

2018

Abstract [1,2,3]Triazolo[4,5-h][1,6]naphthyridines and [1,3]oxazolo[5,4-h][1,6]naphthyridines were synthesized with the aim to investigate their photocytotoxic activity. Upon irradiation, oxazolo-naphtapyridines induced light-dependent cell death at nanomolar/low micromolar concentrations (EC50 0.01–6.59 μM). The most photocytotoxic derivative showed very high selectivity and photocytotoxicity indexes (SI = 72–86, PTI>5000), along with a triplet excited state with exceptionally long lifetime (18.0 μs) and high molar absorptivity (29781 ± 180 M−1cm−1 at λmax 315 nm). The light-induced production of ROS promptly induced an unquenchable apoptotic process selectively in tumor cells, with mitoch…

Pharmaceutical ScienceApoptosisMitochondrionPhotochemiotherapy; Photosensitizing agents; Reactive oxygen species; [123]Triazolo[45-h][16]naphthyridines; [13]oxazolo[54-h][16]naphthyridines; Pharmacology; Drug Discovery; Pharmaceutical Science; Organic Chemistry01 natural sciencesMedicinal chemistry[13]oxazolo[54-h][16]naphthyridinechemistry.chemical_compoundDrug Discovery6]naphthyridineschemistry.chemical_classification0303 health sciencesTumorPhotosensitizing AgentsCell DeathSinglet OxygenSinglet oxygenPhotochemiotherapy; Photosensitizing agents; Reactive oxygen species; [1; 2; 3]Triazolo[4; 5-h][1; 6]naphthyridines; [1; 3]oxazolo[5; 4-h][1; 6]naphthyridines; Apoptosis; Cell Death; Cell Line; Tumor; Humans; Lysosomes; Mitochondria; Naphthyridines; Photochemotherapy; Photosensitizing Agents; Reactive Oxygen Species; Singlet OxygenGeneral MedicineLysosomeMitochondriaExcited stateReactive oxygen specie5-h][1HumanProgrammed cell death2NaphthyridinePhotochemiotherapy3]Triazolo[4Cell Line03 medical and health sciences4-h][1Cell Line TumorHumansNaphthyridines030304 developmental biologyPharmacologyReactive oxygen speciesPhotosensitizing agent010405 organic chemistryOrganic ChemistryApoptosi0104 chemical sciences3]oxazolo[5chemistryPhotochemotherapyCell cultureApoptosis[123]Triazolo[45-h][16]naphthyridine[1LysosomesReactive Oxygen SpeciesDerivative (chemistry)
researchProduct

Monocyte to lymphocyte blood ratio in tuberculosis and HIV patients: Comparative analysis, preliminary data

2017

Recent data confirmed the hypothesis suggested by historical studies that the ratio of peripheral blood monocytes to lymphocytes (M/L) is associated with the risk of tuberculosis (TB) disease. We retrospectively analyzed the electronic health records of tuberculosis and HIV-positive patients who had followed day-care programs at the AIDS Center of the University of Palermo, Italy. 261 patients were recruited and divided into 6 groups as follows: healthy control group (HCG: 47 pts), latent HIV negative infected TB group (LIG, 43 pts), active HIV negative tuberculosis (TAG: 61 pts), treated tuberculosis HIV negative (TTG: 44 pts), HIV drug-naive patients tested TST and QFT-IT-negative with ne…

PharmacologyCo-infected HIV/TBCTuberculosiDrug Discovery3003 Pharmaceutical ScienceCo-infected HIV/TBC; HIV infection; Monocyte to lymphocyte blood RATIO; Tuberculosis; Pharmacology; Drug Discovery3003 Pharmaceutical ScienceMonocyte to lymphocyte blood RATIOHIV infection
researchProduct

Osteoporosis risk factors in HIV positive women with osteoporosis: A retrospective analysis

2017

Multifactorial risk factors such as HIV/HCV co-infection and antiretroviral therapy (ARV) have been associated with osteoporosis in HIV+ women. We retrospectively analysed which known risk factors were associated with the diagnosis of osteoporosis, according to the WHO definition, in HIV positive women who were followed-up at the AIDS Centre of the University of Palermo, Italy between January 2011 and December 2014. Twenty-one HIV+ women with osteoporosis (13 HIV+ mono-infected and 8 HIV/HCV co-infected females) who underwent dual-energy X-ray absorptiometry (DXA) and liver stiffness assessment were included in the study. No significant differences between the HIV and HIV/HCV group were fou…

PharmacologyHIV/HCV infectedAntiretroviral therapy; HIV infected; HIV/HCV infected; Osteoporosis; Osteoporosis risk factors; Pharmacology; Drug Discovery3003 Pharmaceutical ScienceDrug Discovery3003 Pharmaceutical ScienceHIV infectedOsteoporosiOsteoporosis risk factorAntiretroviral therapy
researchProduct

Aza-isoindolo and isoindolo-azaquinoxaline derivatives with antiproliferative activity

2015

Abstract Three new ring systems, pyrido[2′,3′:3,4]pyrrolo[1,2- a ]quinoxalines, pyrido[3′,2′:3,4]pyrrolo[1,2- a ]quinoxalines and pyrido[2′,3′:5,6]pyrazino[2,1- a ]isoindoles, were synthesized through an aza-substitution on the already active isoindolo-quinoxaline system and in particular in the position 7 or 4 of the isoindole moiety and in position 5 of the quinoxaline portion. All new compounds were screened by the National Cancer Institute (Bethesda, MD) against a panel of 60 human tumor cell lines. Biological results of the most active derivatives, with pGI 50 values between 7.09 and 7.27, confirmed the importance of the presence of methoxy substituents for biological activity. The ant…

QuinoxalineIsoindolesAzaisoindolo-quinoxalinesStereochemistryAntiproliferative activity; Apoptosis; Azaisoindolo-quinoxalines; DNA interaction; Isoindolo-azaquinoxalines; Quinoxalines; Antineoplastic Agents; Apoptosis; Aza Compounds; Cell Line Tumor; Cell Proliferation; Dose-Response Relationship Drug; Drug Screening Assays Antitumor; Humans; Isoindoles; Molecular Structure; Quinoxalines; Structure-Activity Relationship; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; Pharmacology; Medicine (all)ApoptosisAntineoplastic AgentsAntiproliferative activityIsoindolesRing (chemistry)Drug Screening AssaysCell LineDose-Response Relationshipchemistry.chemical_compoundStructure-Activity RelationshipQuinoxalineCell Line TumorQuinoxalinesDrug DiscoverymedicineMoietyHumansAntiproliferative activity; Apoptosis; Azaisoindolo-quinoxalines; DNA interaction; Isoindolo-azaquinoxalines; Quinoxalines; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyCell ProliferationPharmacologyAza CompoundsAzaisoindolo-quinoxalineTumorDose-Response Relationship DrugMolecular StructureDrug Discovery3003 Pharmaceutical ScienceMedicine (all)Organic ChemistryApoptosiBiological activityGeneral MedicineAntitumorCell cycleSettore CHIM/08 - Chimica FarmaceuticaDNA interactionSettore ING-IND/22 - Scienza E Tecnologia Dei MaterialiMechanism of actionchemistryIsoindolo-azaquinoxalineDrug Screening Assays Antitumormedicine.symptomDrugIsoindoleIsoindolo-azaquinoxalines
researchProduct